Newsroom

Recent Press Releases

Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma

March 3, 2026

Hepion Pharmaceuticals Successfully Completes Application to the OTCQB

June 25, 2025

Hepion Pharmaceuticals Announces Dr. Kaouthar Lbiati as Interim Chief Executive Officer

June 16, 2025

Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq

May 12, 2025

Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC

May 7, 2025

Hepion Pharmaceuticals Announces Reverse Stock Split

March 14, 2025

Hepion Pharmaceuticals Announces $9.0 Million Public Offering

January 22, 2025

Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd.

December 11, 2024

Pharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson’s Disease Study Group

December 5, 2024

Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B

December 2, 2024

View All Press Releases

Media Contact

Hepion Pharmaceuticals, Inc.
5 Madison Avenue, Suite 400
PMB #4362
Morristown, NJ 07960
+1 416-699-5273
info@hepionpharma.com

Subscribe to Receive News Alerts